{"id":"tamiflu","safety":{"commonSideEffects":[{"rate":"10","effect":"Nausea"},{"rate":"8","effect":"Vomiting"},{"rate":"2","effect":"Headache"},{"rate":"5","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":{"setId":"ee3c9555-60f2-4f82-a760-11983c86e97b","title":"TAMIFLU (OSELTAMIVIR PHOSPHATE) CAPSULE TAMIFLU (OSELTAMIVIR PHOSPHATE) POWDER, FOR SUSPENSION [GENENTECH, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oseltamivir (Tamiflu) is a prodrug that is converted to its active form in the body. The active metabolite binds to and inhibits influenza neuraminidase, an enzyme on the viral surface that cleaves sialic acid receptors. By blocking this enzyme, the drug prevents newly formed virus particles from escaping infected cells and spreading to uninfected cells, thereby reducing viral replication and shortening illness duration.","oneSentence":"Tamiflu inhibits viral neuraminidase, preventing influenza virus particles from being released from infected cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:06.969Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of acute uncomplicated influenza A and B infection in patients ≥2 weeks of age"},{"name":"Prophylaxis of influenza A and B in patients ≥1 year of age"}]},"trialDetails":[{"nctId":"NCT05648448","phase":"PHASE2","title":"A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2023-02-22","conditions":"Influenza, Influenza, Human","enrollment":3000},{"nctId":"NCT04536415","phase":"PHASE4","title":"Bioequivalence Study of Oseltamivir Phosphate and TAMIFLU Under Fed Condition in Healthy Volunteers","status":"COMPLETED","sponsor":"Austarpharma, LLC","startDate":"2020-08-25","conditions":"Bioequivalence","enrollment":96},{"nctId":"NCT04141917","phase":"PHASE4","title":"Test-and-treat for Influenza in Homeless Shelters","status":"TERMINATED","sponsor":"University of Washington","startDate":"2019-11-15","conditions":"Influenza, Respiratory Viral Infection","enrollment":1618},{"nctId":"NCT05378022","phase":"NA","title":"Effects of Nasal-spraying LiveSpo Navax in Treatment of Influenza Virus in Children","status":"COMPLETED","sponsor":"National Children's Hospital, Vietnam","startDate":"2020-12-21","conditions":"Acute Respiratory Tract Infections","enrollment":70},{"nctId":"NCT03520049","phase":"PHASE3","title":"Proof-of-Concept: A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Unity Health Toronto","startDate":"2016-11","conditions":"Immune Thrombocytopenia","enrollment":30},{"nctId":"NCT02949011","phase":"PHASE3","title":"Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications","status":"COMPLETED","sponsor":"Shionogi","startDate":"2017-01-11","conditions":"Influenza","enrollment":2184},{"nctId":"NCT00844155","phase":"NA","title":"Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir in the Intensive Care Unit","status":"WITHDRAWN","sponsor":"University of Manitoba","startDate":"2009-03","conditions":"Influenza A Virus Infection, Influenza B Virus Infection","enrollment":""},{"nctId":"NCT02954354","phase":"PHASE3","title":"A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza","status":"COMPLETED","sponsor":"Shionogi","startDate":"2016-12-08","conditions":"Influenza","enrollment":1436},{"nctId":"NCT01715909","phase":"PHASE1","title":"A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-22","conditions":"Influenza","enrollment":20},{"nctId":"NCT00988325","phase":"PHASE1","title":"A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-01","conditions":"Influenza","enrollment":65},{"nctId":"NCT02780622","phase":"PHASE4","title":"A Pharmacokinetics, Pharmacodynamics and Safety Study of Warfarin in Combination With Tamiflu (Oseltamivir)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-02","conditions":"Drug Therapy, Combination","enrollment":20},{"nctId":"NCT02507648","phase":"PHASE1","title":"A Bioequivalence Study of Oseltamivir From Oseltamivir 75 mg Caps (Pharmacare PLC, Palestine) and Tamiflu® 75 mg Caps (Hoffmann-La Roche, Switzerland)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2013-03","conditions":"Healthy","enrollment":24},{"nctId":"NCT02262715","phase":"PHASE1","title":"A Study to Assess the Drug-Drug Interaction Between VX-787 and Oseltamivir","status":"COMPLETED","sponsor":"Janssen Infectious Diseases BVBA","startDate":"2014-07","conditions":"Healthy","enrollment":38},{"nctId":"NCT00979251","phase":"PHASE2","title":"Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects","status":"COMPLETED","sponsor":"Adamas Pharmaceuticals, Inc.","startDate":"2009-09","conditions":"Influenza","enrollment":2},{"nctId":"NCT01050257","phase":"PHASE3","title":"A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Influenza","enrollment":118},{"nctId":"NCT00391768","phase":"PHASE1, PHASE2","title":"Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-01","conditions":"Influenza","enrollment":87},{"nctId":"NCT01130636","phase":"PHASE4","title":"Observational Study on the Pharmacokinetics of Oseltamivir in the Treatment of Influenza During Lactation","status":"COMPLETED","sponsor":"Pharmahungary Group","startDate":"2010-06","conditions":"Influenza","enrollment":6},{"nctId":"NCT01048879","phase":"PHASE4","title":"Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2009-10","conditions":"Critically Ill Renal Failure Requiring CVVHD and Oseltamivir, Critically Ill Requiring ECMO and Oseltamivir","enrollment":15},{"nctId":"NCT00311701","phase":"","title":"Chart Review of Antivirals for Influenza in Infants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-11","conditions":"Influenza","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":572,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tamiflu®","genericName":"Tamiflu®","companyName":"Genuine Research Center, Egypt","companyId":"genuine-research-center-egypt","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tamiflu inhibits viral neuraminidase, preventing influenza virus particles from being released from infected cells. Used for Treatment of acute uncomplicated influenza A and B infection in patients ≥2 weeks of age, Prophylaxis of influenza A and B in patients ≥1 year of age.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}